research Alopecia: Kids are not just little people
Hair loss in children is diagnosed and treated differently than in adults, with different common causes and a focus on less invasive methods.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Inhibition of T-cell activity in alopecia areata: recent developments and new directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives
The document concludes that proper treatment and management of plaque psoriasis in adolescents can improve their quality of life.
research A small scale study to evaluate the efficacy of microneedling in the presence or absence of platelet‐rich plasma in the treatment of post‐clipping alopecia in dogs
Microneedling with platelet-rich plasma helps dog hair regrow faster than microneedling alone.
research Reduced Levels of Serum 25-Hydroxyvitamin D in Alopecia Areata: A Systematic Review and Meta-analysis
People with alopecia areata often have lower vitamin D levels than healthy people.
research An Update on Alopecia and its Association With Thyroid Autoimmune Diseases
People with alopecia have a higher risk of thyroid cancer.
research Estimation of Claudin 3 in the Sreum of Alopecia Areata Patients and Its Association with Disease Severity
Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.
research Therapeutic Updates on Lichen planopilaris and Frontal Fibrosing Alopecia: A Systematic Review
Antimalarial agents are effective for LPP, and intralesional steroids are effective for FFA.
research Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease‐associated psychological morbidity
Alopecia areata involves immune system imbalances that may lead to depression and anxiety.
research A novel therapeutic paradigm for patients with extensive alopecia areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research Immunization and Bacterial Pathogens in the Oropharynx as Risk Factors for Alopecia Areata
Immunization and throat bacteria may increase the risk of a hair loss condition called alopecia areata.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
New treatments for Alopecia Areata show promise but need to be more effective and affordable.
research Understanding autoimmunity of vitiligo and alopecia areata
Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
research A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Treatment of alopecia areata in pre‐adolescent children with oral tofacitinib: A retrospective study
Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
research Total Glucosides of Paeony Capsule Plus Compound Glycyrrhizin Tablets for the Treatment of Severe Alopecia Areata in Children: A Randomized Controlled Trial
TGPC plus CGT is effective and safe for treating severe alopecia areata in children.
research Sequential high‐ and low‐dose systemic corticosteroid therapy for severe childhood alopecia areata
High and low doses of prednisolone helped 62% of children with severe alopecia regrow hair with some weight gain and mild acne as side effects.
research Alopecia Areata
Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.
research Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients
Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Alopecia areata: medical treatments
Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
research Plasma rico en plaquetas como terapia autóloga en la medicina regenerativa: Revisión narrativa
El plasma rico en plaquetas puede ayudar en la regeneración celular y podría ser útil en tratamientos complementarios para enfermedades sin cura específica.